Harvard Bioscience(HBIO)
Search documents
Harvard Bioscience(HBIO) - 2024 Q2 - Quarterly Report
2024-08-08 13:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorpo ...
Harvard Bioscience Announces Second Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-08-08 12:30
HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, "Second quarter revenues reflect a more challenging than expected market environment. With the uncertainty of the timing for market recovery we stayed focused on managing costs and the actions we implemented during Q2 are expected to drive annualized savings of approximately $4 million whil ...
Harvard Bioscience(HBIO) - 2024 Q2 - Quarterly Results
2024-08-08 12:29
Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2024 Financial Results HOLLISTON, Mass., August 8, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, "Second quarter revenues reflect a more challenging than expected market environment. With the uncertainty of the timing for market recovery we stayed focused on managing costs and the actions we implemented du ...
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
Newsfilter· 2024-08-02 12:00
HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast ...
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
GlobeNewswire News Room· 2024-08-02 12:00
HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast ...
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
GlobeNewswire News Room· 2024-06-06 20:05
HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024. About Harvard Bioscience, Inc. For more information, please visit our website at www.harvardbioscience.com. The Company's presentation is scheduled f ...
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
Newsfilter· 2024-06-06 20:05
About Harvard Bioscience, Inc. Company Contact: Three Part Advisors Sandy Martin / Erol Girgin / William Shelmire HBIO@threepa.com (214) 616-2207 The Company's presentation is scheduled for 2:45-3:20 PM ET on June 12th. The Company will also host oneon-one investor meetings throughout the day. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website at https://investor.harvardbioscience.com. A replay will be available shortly after th ...
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
globenewswire.com· 2024-05-16 20:05
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentation, or to schedul ...
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
Newsfilter· 2024-05-16 20:05
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentation, or to schedule ...
Harvard Bioscience(HBIO) - 2024 Q1 - Quarterly Report
2024-05-07 21:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorp ...